恩格列净在心血管风险谱中一致降低死亡与心衰住院:EMPA-REG OUTCOME 分析
EMPA-REG OUTCOME 试验纳入 2 型糖尿病合并动脉粥样硬化性心血管疾病患者,按基线 TIMI 二级预防风险评分及既往心梗/卒中分层分析。结果显示,恩格列净对比安慰剂在心血管死亡、全因死亡、3 点 MACE 和心衰住院方面的相对风险降低在各风险亚组中一致,交互作用 P>0.05。
要点
- 恩格列净降低心血管死亡、全因死亡、3 点 MACE 和心衰住院的风险在各基线心血管风险亚组中一致。
- 既往心梗或卒中与 TIMI 风险评分亚组间无显著交互作用(P>0.05)。
- 尽管所有患者均有动脉粥样硬化性心血管疾病,基线心血管事件风险谱广泛。
核心结论
- 恩格列净对比安慰剂在广泛心血管风险谱中一致降低心血管死亡、全因死亡、3 点 MACE 和心衰住院风险。
研究设计与样本
- EMPA-REG OUTCOME 试验事后分析,纳入 7020 例接受研究药物的 2 型糖尿病合并动脉粥样硬化性心血管疾病患者。
- 按基线既往心梗/卒中及 TIMI 二级预防风险评分(≤2、3、4、≥5 分)分层,分析合并恩格列净与安慰剂组的结局。
主要发现
- 65% 患者有既往心梗或卒中;按 TIMI 评分低、中、高、最高风险分别占 12%、40%、30%、18%。
- 安慰剂组 3 点 MACE 在低、中、高、最高风险组发生率分别为 7.3%、9.4%、12.6%、20.6%。
- 恩格列净对比安慰剂对心血管死亡、全因死亡、3 点 MACE 和心衰住院的相对风险降低在既往心梗/卒中及 TIMI 评分亚组中一致(交互作用 P>0.05)。
临床怎么用
- 对于 2 型糖尿病合并动脉粥样硬化性心血管疾病的患者,无论基线心血管风险高低,恩格列净的心血管获益一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease, in comparison with placebo, empagliflozin reduced the risks of 3-point major adverse cardiovascular events (3-point MACE), cardiovascular and all-cause death, and hospitalization for heart failure. We investigated whether these effects varied across the spectrum of baseline cardiovascular risk. METHODS: Cardiovascular death, all-cause mortality, 3-point MACE, and hospitalization for heart failure in the pooled empagliflozin and placebo groups were analyzed in subgroups by prior myocardial infarction and stroke at baseline, and by estimated baseline cardiovascular risk based on the 10-point TIMI (Thrombolysis In Myocardial Infarction) Risk Score for Secondary Prevention. RESULTS: Of 7020 patients who received the study drug, 65% had a prior myocardial infarction or stroke, and 12%, 40%, 30%, and 18% were at low, intermediate, high, and highest estimated cardiovascular risk according to TIMI Risk Score for Secondary Prevention (≤2, 3, 4, and ≥5 points, respectively). In the placebo group, 3-point MACE occurred during the trial in 7.3%, 9.4%, 12.6%, and 20.6% of patients at low, intermediate, high, and highest estimated baseline risk, respectively. Relative reductions in risk of cardiovascular death, all-cause mortality, 3-point MACE and hospitalization for heart failure with empagliflozin versus placebo were consistent in patients with and without prior myocardial infarction and/or stroke and across subgroups by TIMI Risk Score for Secondary Prevention at baseline ( P>0.05 for randomized group-by-subgroup interactions). CONCLUSIONS: Despite all patients having atherosclerotic cardiovascular disease, patients in EMPA-REG OUTCOME demonstrated a broad risk spectrum for cardiovascular events. Reductions in key cardiovascular outcomes and mortality with empagliflozin versus placebo were consistent across the range of cardiovascular risk. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01131676.
引用
- Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019. PMID: 30586757. doi:10.1161/CIRCULATIONAHA.118.037778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。